CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+11.97%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.01B
AUM Growth
+$1.01B
(+13%)
Cap. Flow
+$59.9M
Cap. Flow
% of AUM
5.9%
Top 10 Holdings %
Top 10 Hldgs %
71.7%
Holding
40
New
2
Increased
7
Reduced
9
Closed
4
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$112M |
| 2 |
Illumina
ILMN
|
$40.1M |
| 3 |
BioLife Solutions
BLFS
|
$15.1M |
| 4 |
Neurogene
NGNE
|
$10.2M |
| 5 |
Intellia Therapeutics
NTLA
|
$8.29M |
Top Sells
| 1 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$87.8M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$21.7M |
| 3 |
Structure Therapeutics
GPCR
|
$6.78M |
| 4 |
MaxCyte
MXCT
|
$5.9M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$4.15M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Revolution Medicines
RVMD
$7.1B
| $164M | 16.09% | 5,714,775 +3,904,775 | +216% | +$112M |
|
|
2
BioLife Solutions
BLFS
$1.2B
| $141M | 13.89% | 8,707,165 +927,165 | +12% | +$15.1M |
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $97.1M | 9.53% | 1,006,500 -3,830 | -0.4% | -$369K |
|
4
Relay Therapeutics
RLAY
$619M
| $81.3M | 7.98% | 7,387,943 +464,369 | +7% | +$5.11M |
|
|
5
Structure Therapeutics
GPCR
$1.11B
| $44.5M | 4.37% | 1,091,867 -166,299 | -13% | -$6.78M |
|
|
6
Intellia Therapeutics
NTLA
$1.22B
| $44.2M | 4.34% | 1,450,000 +271,925 | +23% | +$8.29M |
|
|
7
Illumina
ILMN
$15.8B
| $43.6M | 4.28% | 313,000 +288,000 | +1,152% | +$40.1M |
|
|
VERV
8
DELISTED
Verve Therapeutics
VERV
| $41.9M | 4.12% | 3,009,094 +54,384 | +2% | +$758K |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $37.3M | 3.66% | 195,000 -5,000 | -3% | -$957K |
|
|
SLGC
10
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $31.9M | 3.13% | 12,604,275 | – | – |
|
11
Exact Sciences
EXAS
$8.98B
| $31.1M | 3.05% | 420,000 -39,450 | -9% | -$2.92M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $30.1M | 2.96% | 326,378 -45,000 | -12% | -$4.15M |
|
13
Pliant Therapeutics
PLRX
$101M
| $28.6M | 2.8% | 1,577,108 | – | – |
|
14
Denali Therapeutics
DNLI
$2.23B
| $27.9M | 2.74% | 1,300,000 | – | – |
|
15
4D Molecular Therapeutics
FDMT
$288M
| $20.9M | 2.06% | 1,033,811 | – | – |
|
16
Tenaya Therapeutics
TNYA
$184M
| $20.7M | 2.03% | 6,381,377 | – | – |
|
17
Beam Therapeutics
BEAM
$1.66B
| $14.4M | 1.41% | 528,000 -42,000 | -7% | -$1.14M |
|
18
AbCellera Biologics
ABCL
$1.25B
| $13.5M | 1.32% | 2,360,129 | – | – |
|
19
Tango Therapeutics
TNGX
$747M
| $11.8M | 1.15% | 1,188,349 -119,000 | -9% | -$1.18M |
|
20
Century Therapeutics
IPSC
$42.5M
| $10.6M | 1.04% | 3,206,380 | – | – |
|
21
Avidity Biosciences
RNA
$5.99B
| $10.6M | 1.04% | 1,175,750 -74,250 | -6% | -$672K |
|
|
22
Neurogene
NGNE
$264M
| $10.2M | 1% | +524,616 | New | +$10.2M |
|
23
Pacific Biosciences
PACB
$393M
| $10.2M | 1% | 1,035,859 | – | – |
|
24
GeneDx Holdings
WGS
$3.72B
| $8.51M | 0.84% | 3,095,511 | – | – |
|
25
Fate Therapeutics
FATE
$120M
| $7.67M | 0.75% | 2,050,000 | – | – |
|